ImpediMed Limited (ASX:IPD)
Australia
· Delayed Price · Currency is AUD | Market Cap | 32.62M |
| Revenue (ttm) | 14.23M |
| Net Income (ttm) | -24.37M |
| Shares Out | 2.04B |
| EPS (ttm) | -0.01 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,452,882 |
| Average Volume | 8,320,567 |
| Open | 0.0160 |
| Previous Close | 0.0170 |
| Day's Range | 0.0160 - 0.0170 |
| 52-Week Range | 0.0150 - 0.0590 |
| Beta | 1.31 |
| RSI | 33.88 |
| Earnings Date | Apr 24, 2026 |
About ImpediMed
ImpediMed Limited, a medical technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) technology medical devices and software services in Australia, Europe, the United States, and internationally. The company offers SOZO, a noninvasive BIS device for the clinical assessment of lymphedema, which uses bioimpedance measurements to assess fluid levels and tissue composition; L-Dex analysis for lymphedema; BodyComp Analysis, a point-of-care body composition analysis; and HF-Dex analysis for point-of-care heart failure fl... [Read more]
Financial Performance
In fiscal year 2025, ImpediMed's revenue was 12.72 million, an increase of 23.31% compared to the previous year's 10.32 million. Losses were -23.24 million, 17.4% more than in 2024.
Financial StatementsNews
ImpediMed Limited (IPDQF) Q2 2026 Earnings Call Transcript
ImpediMed Limited (IPDQF) Q2 2026 Earnings Call Transcript
ImpediMed Limited (IPDQF) Q1 2026 Earnings Call Transcript
ImpediMed Limited (OTCPK:IPDQF) Q1 2026 Earnings Call October 29, 2025 6:00 PM EDT Company Participants Parmjot Bains - MD, CEO & Director Scott Long - Senior Vice President of US Sales, Key Accounts,...